Bionomics (BNO) - Merck thinks BNC375 is unforgettable, too | Analyst: Stuart Roberts | Rating: Buy TP:$1.10 | Bionomics has secured a new research...
Bionomics (BNO) - Merck thinks BNC375 is unforgettable, too | Analyst: Stuart Roberts | Rating: Buy TP:$1.10 | Bionomics has secured a new research collaboration with Merck & Co.. They have partnered with Bionomics on BNC375, which in pre-clinical has shown evidence that it can treat Alzheimer's disease as well as other disorders of the Central Nervous System (CNS). Merck will now fund all R&D related to BNC375, and will pay Bionomics US$20m upfront and US$506m in milestone payments to access the programme. This is a remarkable deal for a drug that has yet to be taken to the clinic and evidence both of the high demand for new Alzheimer's drugs from Big Pharma, and the quality of Bionomics' R&D in the CNS field.
Welcome to Livewire, Australia’s most trusted source of investment insights and analysis.
To continue reading this wire and get unlimited access to Livewire, join for free now and become a more informed and confident investor.
Over 25 years’ experience in the finance/tech industry. Mathan has worked extensively in all parts of the finance sector (i.e. County NatWest, Citi, LIM, Southern Cross, Bell Potter, Baillieu Holst and Blue Ocean Equities). Currently Founder and...
Please sign in to comment on this wire.